TABLE 2.
Base case results.
| Strategy | Total cost | LY | QALY | ICERa |
|---|---|---|---|---|
| Sunitinib | 239257.68 | 2.99 | 2.13 | Dominated |
| Avelumab + axitinib | 432403.81 | 3.07 | 2.32 | Dominated |
| Nivolumab + ipilimumab | 306201.03 | 3.21 | 2.42 | Dominated |
| Lenvatinib + pembrolizumab | 562080.09 | 3.44 | 2.61 | Dominated |
| Pembrolizumab + axitinib | 270957.76 | 3.31 | 2.52 | 81,282 |
| Nivolumab + cabozantinib | 484051.49 | 3.91 | 2.99 | 453391 |
LY, life year; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.
a
The ICER was compared with the next best nondominated option.